Literature DB >> 25073901

Can understanding the virulence mechanisms of RNA viruses lead us to a vaccine against eastern equine encephalitis virus and other alphaviruses?

Derek W Trobaugh1, Kate D Ryman, William B Klimstra.   

Abstract

Eastern equine encephalitis virus (EEEV) is a highly neurovirulent mosquito-borne alphavirus that causes severe morbidity and mortality upon human infection. Recent emergence of EEEV into nonendemic regions in the USA and Panama demonstrates the need for the development of an effective EEEV vaccine for licensure for human use. The current EEEV vaccine is available to only at-risk laboratory workers but is poorly immunogenic and requires multiple boosters. In this editorial, we summarize recent developments in understanding alphavirus virulence mechanisms that could be utilized to rationally design a live attenuated vaccine against EEEV or other alphaviruses.

Entities:  

Keywords:  EEEV; VEEV; alphavirus; live attenuated vaccine; rational design; virulence mechanisms

Mesh:

Substances:

Year:  2014        PMID: 25073901      PMCID: PMC4381809          DOI: 10.1586/14760584.2014.944168

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  24 in total

1.  Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice.

Authors:  K A Bernard; W B Klimstra; R E Johnston
Journal:  Virology       Date:  2000-10-10       Impact factor: 3.616

2.  17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005.

Authors:  Alan D T Barrett; Thomas P Monath; Veronique Barban; Matthias Niedrig; Dirk E Teuwen
Journal:  Vaccine       Date:  2006-12-28       Impact factor: 3.641

3.  Severe encephalitis in cynomolgus macaques exposed to aerosolized Eastern equine encephalitis virus.

Authors:  Douglas S Reed; Matthew G Lackemeyer; Nicole L Garza; Sarah Norris; Scott Gamble; Lawrence J Sullivan; Cathleen M Lind; Jo Lynne Raymond
Journal:  J Infect Dis       Date:  2007-06-21       Impact factor: 5.226

4.  Isolation of the vaccine strain of Venezuelan equine encephalomyelitis virus from mosquitoes in Louisiana.

Authors:  C E Pedersen; D M Robinson; F E Cole
Journal:  Am J Epidemiol       Date:  1972-05       Impact factor: 4.897

5.  An inactivated eastern equine encephalomyelitis vaccine propagated in chick-embryo cell culture. II. Clinical and serologic responses in man.

Authors:  P J Bartelloni; R W McKinney; T P Duffy; F E Cole
Journal:  Am J Trop Med Hyg       Date:  1970-01       Impact factor: 2.345

6.  Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine.

Authors:  P R Pittman; R S Makuch; J A Mangiafico; T L Cannon; P H Gibbs; C J Peters
Journal:  Vaccine       Date:  1996-03       Impact factor: 3.641

7.  A viral RNA structural element alters host recognition of nonself RNA.

Authors:  Jennifer L Hyde; Christina L Gardner; Taishi Kimura; James P White; Gai Liu; Derek W Trobaugh; Cheng Huang; Marco Tonelli; Slobodan Paessler; Kiyoshi Takeda; William B Klimstra; Gaya K Amarasinghe; Michael S Diamond
Journal:  Science       Date:  2014-01-30       Impact factor: 47.728

8.  Analysis of Venezuelan equine encephalitis virus capsid protein function in the inhibition of cellular transcription.

Authors:  Natalia Garmashova; Svetlana Atasheva; Wenli Kang; Scott C Weaver; Elena Frolova; Ilya Frolov
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

9.  A five-amino-acid deletion of the eastern equine encephalitis virus capsid protein attenuates replication in mammalian systems but not in mosquito cells.

Authors:  Patricia V Aguilar; Lawrence W Leung; Eryu Wang; Scott C Weaver; Christopher F Basler
Journal:  J Virol       Date:  2008-05-14       Impact factor: 5.103

10.  RNA viruses can hijack vertebrate microRNAs to suppress innate immunity.

Authors:  Derek W Trobaugh; Christina L Gardner; Chengqun Sun; Andrew D Haddow; Eryu Wang; Elik Chapnik; Alexander Mildner; Scott C Weaver; Kate D Ryman; William B Klimstra
Journal:  Nature       Date:  2013-12-18       Impact factor: 49.962

View more
  4 in total

1.  Electroporation of Alphavirus RNA Translational Reporters into Fibroblastic and Myeloid Cells as a Tool to Study the Innate Immune System.

Authors:  Christina L Gardner; Derek W Trobaugh; Kate D Ryman; William B Klimstra
Journal:  Methods Mol Biol       Date:  2016

2.  Enhancing the yield of seasonal influenza viruses through manipulation of microRNAs in Madin-Darby canine kidney cells.

Authors:  Suthat Saengchoowong; Pattaraporn Nimsamer; Kritsada Khongnomnan; Witthaya Poomipak; Kesmanee Praianantathavorn; Somruthai Rattanaburi; Yong Poovorawan; Qibo Zhang; Sunchai Payungporn
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-06

3.  Designing multivalent immunogens for alphavirus vaccine optimization.

Authors:  C M Read; Kenneth Plante; Grace Rafael; Shannan L Rossi; Werner Braun; Scott C Weaver; Catherine H Schein
Journal:  Virology       Date:  2021-02-05       Impact factor: 3.513

4.  Rational design of a live-attenuated eastern equine encephalitis virus vaccine through informed mutation of virulence determinants.

Authors:  Derek W Trobaugh; Chengqun Sun; Matthew D Dunn; Douglas S Reed; William B Klimstra
Journal:  PLoS Pathog       Date:  2019-02-11       Impact factor: 6.823

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.